Abstract
In the continuing search for new cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD), reasonable candidates are the secretase enzymes involved in the processing of the amyloid precursor protein (APP), as well as the large proteolytic cleavage fragments sAPPα and sAPPβ. The enzymatic activities of some of these secretases, such as BACE1 and TACE, have been investigated as potential AD biomarkers, and it has been assumed that these activities present in human CSF result from the soluble truncated forms of the membrane-bound enzymes. However, we and others recently identified soluble forms of BACE1 and APP in CSF containing the intracellular domains, as well as the multi-pass transmembrane presenilin-1 (PS1) and other subunits of γ-secretase. We also review recent findings that suggest that most of these soluble transmembrane proteins could display self-association properties based on hydrophobic and/or ionic interactions leading to the formation of heteromeric complexes. The oligomerization state of these potential new biomarkers needs to be taken into consideration for assessing their real potential as CSF biomarkers for AD by adequate molecular tools.
Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder recognized as the most common cause of dementia among the elderly. The pathologic characteristics of AD are neurodegeneration and proteinaceous deposits, including extracellular plaques composed mostly of β-amyloid peptides (Aβ) and intracellular tangles of the microtubule-associated protein tau abnormally hyperphosphorylated (P-tau). Both pathological effectors, Aβ and P-tau, can be monitored in cerebrospinal fluid (CSF). In late-onset AD, concentrations of tau and P-tau in CSF are increased and probably reflect neuronal damage, but levels of Aβ peptides are decreased. These changes can be measured in CSF before the onset of any other symptoms, and, therefore, they can be used as a diagnostic marker for the disease [for a recent review, see Ref. ()]. Although numerous laboratories have reported increased levels of P-tau and total tau (T-tau) in the CSF of AD patients, they are not specific, and also increase in other neuropathological disorders (, ). It is well recognized that Aβ peptides, and especially the Aβ42 species, are the most specific CSF biomarkers for AD.
According to the amyloid hypothesis, accumulation of Aβ in the brain, resulting from an imbalance between production and clearance, is the primary influence driving AD pathogenesis (). The Aβ peptide is generated by processing a larger type I transmembrane spanning glycoprotein, the amyloid precursor protein (APP), through the successive action of proteolytic enzymes called secretases. Sequential processing of APP begins with either the action of α-secretase or β-secretase, followed by γ-secretase cleavage. When cleavage is carried out by β- and γ-secretase, the so-called amyloidogenic pathway, a 36–43 amino acid peptide is generated since γ-secretase acts on a domain with multiple potential cleavage sites (). The Aβ40 peptide is the most common species, while the Aβ42 variant is the most amyloidogenic form of the peptide associated with AD progression. However, in the non-pathological condition, the majority of APP molecules are cleaved through the non-amyloidogenic pathway by the sequential action of α- and γ-secretases. α-Secretase cleaves APP within the Aβ domain, precluding the generation of the Aβ peptide [for a review, see Ref. ()]. The existence in CSF of several shorter isoforms in addition to Aβ40 and Aβ42 has been explained by an alternative APP processing pathway involving concerted cleavages of APP by α- and β-secretase ().
The predisposition for self-association of Aβ42 determines that while Aβ42 content is increased in the AD brain, its levels in CSF are decreased presumably due to its increasing deposition in brain tissue (). In this context, with two dynamics playing out in opposite directions within the brain, increasing Aβ production and increasing deposition, the interpretation of CSF changes in Aβ levels in pre-symptomatic stages seems difficult. In fact, Jack et al. () proposed that Aβ-plaque biomarkers are dynamic early in the disease before the appearance of clinical symptoms, but have largely reached a plateau by the time clinical symptoms appear, determining that CSF Aβ does not change significantly over time in patients with AD. Moreover, in this context, it is difficult to anticipate, thus to evaluate, the outcomes expected from the CSF biochemical assessments of Aβ in AD subjects consequence of effective therapy with β- or γ-secretase inhibitors, potential disease-modifying therapeutics under development (, ).
In accordance with the mentioned challenges, there is a need to identify additional β-amyloid-related markers of AD. Reasonable candidates are proteins, such as secretases, involved in the pathological processing of APP, and the large proteolytic cleavage fragments sAPPα and sAPPβ. Since most of these secretases are transmembrane proteins, their assessments in CSF were not considered until recent years. The purpose of this article is to review recent evidence about the presence of secretase components in CSF and their potential as AD biomarkers. In addition, we summarize our recent findings about the presence of soluble full-length APP (sAPPf) in CSF and their oligomerization into heteromers. Our studies demonstrated that sAPP heteromers contribute to the estimation of sAPPα and sAPPβ levels, which needs to be taken into consideration for their assessment by ELISA. The suitability of applying adequate molecular tools for the assessment in CSF of hydrophobic proteins and soluble heteromeric aggregates is absolutely necessary to evaluate their potential as biomarkers.
Soluble Full-Length and Heteromers of sAPP in CSF
The processing of APP begins with the action of either α-secretase or β-secretase, initiating mandatory pathways. The initial shedding by α-secretase or β-secretase releases large soluble proteolytic cleavage fragments of APP, sAPPα and sAPPβ, respectively, both present in human CSF (, ). Since amyloidogenic processing of APP is expected to be altered in the Alzheimer brain, both large sAPP fragments have been postulated as potential new AD biomarkers, but no consistent changes in CSF sAPPα and sAPPβ levels have been identified to date [see review by Perneczkyet al.()]. Interestingly, it has been suggested that full-length APP containing an intact cytoplasmic domain also exists as a soluble form (sAPPf) (, ). Recently, we confirmed that sAPPf is present in human CSF and demonstrated its contribution when estimating levels of large sAPP fragments (). In consequence, the 6E10 antibody, a widely used anti-APP antibody that recognizes an epitope present in sAPPα and absent in sAPPβ, will detected not only sAPPα, but also sAPPf in CSF. Therefore, the use of 6E10 or similar antibodies in contraposition to pan-specific antibodies for the C-terminus of sAPPα should be considered as a contributing factor for contradictory findings between laboratories. Moreover, we have demonstrated that sAPPf co-exists in CSF with sAPPα and sAPPβ, and all forms are capable of assembling into heteromers [(); see also Figure 1A]. The APP oligomerization status is particularly relevant, since most quantification of sAPPα and sAPPβ in CSF from AD subjects relies on ELISA determinations developed for monomeric species. Our data indicate that sAPP heteromers interfere with the measurement of sAPPα and sAPPβ in commercially available ELISA kits. Interestingly, an unexpected positive correlation has been consistently reported between both forms, indicating a similar shift for sAPPα and sAPPβ levels (–). Since the production of sAPPβ should be inversely proportional to that of sAPPα, this is an unexpected finding that we attributed, at least in part, to the existence of sAPPα/sAPPβ heteromers. In this context, early studies assessing sAPPα and sAPPβ levels by Western blot failed to demonstrate this positive correspondence (). The assessment of sAPPα/sAPPβ levels is also of interest to monitor the biochemical effect of drugs targeting Aβ in clinical trials (), particularly for β-/γ-secretase inhibitors since discouraging reports question this therapeutic strategy, even the amyloid cascade hypothesis (). In this regard, β-secretase inhibition resulted in sAPPβ significant decrease, but also in increased concentration of sAPPα (), suggesting that inhibition of β-secretase in humans resulted in a compensatory increase in non-amyloidogenic APP cleavage. The simultaneous determination of sAPPα and sAPPβ in CSF by protocols that prevents underestimation by heteromeric association is mandatory.
Figure 1
In conclusion, an optimal approach to quantify sAPPα and sAPPβ in CSF has been based on ELISA determinations, but the presence of heteromeric complexes of sAPP obligate adjusting protocols. Moreover, the characterization of a soluble transmembrane protein might be hindered by the difficulty in distinguishing it from the truncated species generated by cleavage of the transmembrane protein. The existence of different sAPP isoforms, generated from alternative exon splicing (), adds complexity to the determination of sAPP as CSF biomarkers, but needs to be taken into consideration since large species of sAPP, which should correspond to APP751/770, appeared to increase AD CSF (). Analysis of sAPPf splicing isoforms may be of particular interest and needs to be more specifically addressed. More research is needed to design an appropriate strategy and assays for CSF sAPP. The validation of sAPP as a CSF biomarker may be of particular interest for assessing the effect of clinical trials based on β-secretase inhibition, where a decrease in newly generated sAPPβ is expected, but with an unclear effect on newly generated sAPPα ().
β-Secretase and TACE/α-Secretase Activities in CSF
The major neuronal β-secretase has been identified as beta-site APP cleaving enzyme 1 [BACE1; ()], though other proteases such as BACE2 and cathepsins might be involved as well (, ). Interestingly, both BACE1 protein and activity levels can be measured in CSF (), but, to date, accurate determination of BACE1 remains a great challenge and there is no consensus as to whether its levels are consistently affected in CSF as dementia progresses (). Most published results suggest that BACE1 activity increases in AD, preferentially in MCI cases with prodromal AD (, , ). However, such biochemical analysis often relies on APP fluorogenic substrates with modified APP β-cleavage sites, whose discrimination between BACE1 from other β-secretase enzymes like BACE2 and cathepsins is unclear [for a review, see Ref. ()]. Currently, it is not known whether BACE1 activity reflects BACE1 protein content since it correlates poorly (), and it is also unknown if the values measured are due to full-length BACE1 or a truncated form. Mature BACE1 holoprotein contains a single transmembrane domain and a short intracellular C-terminal (). Membrane-bound BACE1 can be partly cleaved within its extracellular domain to generate soluble BACE1 for secretion (, ). Accordingly, it has been assumed that the BACE1 present in CSF is a truncated soluble form of the originally membrane-bound BACE1 missing the transmembrane and intracellular domains (). Indeed, some studies failed to demonstrate the presence of BACE1 containing the C-terminal domain in human CSF and plasma (, ), but others detected immunoreactivity with BACE1 C-terminal antibodies (, , ), suggesting that full-length BACE1 exists in this fluid. The presence of full-length BACE1, together with its truncated form, has also been demonstrated in conditioned media from cultured neurons (). The presence in CSF of an immature form of BACE1 protein, poorly active or inactive, has also been suggested (). Future work will be required to elucidate if both the full-length and truncated BACE1 account for β-secretase in CSF.
Furthermore, similarly to APP, BACE1 occurred as a dimer in human brain tissue (, ). Therefore, we cannot discard the occurrence of BACE1 forming complexes in CSF, which needs to be taken into consideration, especially for the attempts to develop BACE1 ELISA assays (, ). In conclusion, extensive work remains to be accomplished to reinforce the interest of using CSF BACE1 levels and activity as AD biomarkers.
Regarding α-secretase, at least three members of the ADAM (a disintegrin and metalloproteinase) family, ADAM10, ADAM17 (TACE), and ADAM9 have been proposed as α-secretases (), and other ADAM family members, such as ADAM8, has also demonstrated efficiency in cleavage of APP (). Evidence indicates that ADAM10, but not ADAM9 or ADAM17, is the enzyme acting as a physiologically relevant constitutive α-secretase in vivo (, ). To our knowledge, the occurrence of ADAM-10/α-secretase activity in either CSF or plasma has not been reported to date, and ADAM10 has so far only been found in platelets () and other blood cells (). However, elevated activity levels for ADAM17/TACE activity have been found in both CSF () and plasma (, ) from subjects with AD. TACE releases several transmembrane proteins into soluble forms, including APP, but also tumor necrosis factor α (TNFα) receptors (). The synthetic peptide used for TACE enzymatic activity assays in CSF and plasma consists of a TACE-sensitive TNF sequence surrounding the TACE-specific cleaving site (); thus, it constitutes a substrate favorable for TACE compared to ADAM10. α-Secretase accurately refers to the activity targeting APP and generating sAPPα; nonetheless, the general requirements for secretase cleavage are not strict and we cannot exclude the possibility that other enzymes, including ADAM10, may cleave peptides in human CSF and plasma. The presence in CSF of other ADAM family members, including ADAM10, deserves study.
Moreover, ADAM proteases, similarly to BACE1, are type I transmembrane proteins, but also include secreted isoforms (). Indeed, ADAM10 and ADAM17 have been shown to be secreted outside the cells in exosomes (). Thus, the occurrence of TACE activity in CSF and plasma has been attributed to soluble isoforms shedding from cell membranes after the cleavage of TNFα and the TNF receptors. Nonetheless, TACE protein has only been studied in plasma by Western blot using an anti-TACE polyclonal antibody (), but not by the combination of N- and C-terminal antibodies allowing characterization of the full-length and truncated forms. Again, a parallel study of protein and enzyme activity is pending in order to define the most sensitive molecular tools necessary for using ADAM as CSF biomarkers.
Presenilin-1 and Other γ-Secretase Components are Present in CSF
γ-Secretase is an intramembrane protease complex composed of presenilin-1 (PS1), nicastrin, APH1 (anterior pharynx-defective 1), and PEN2 (presenilin enhancer 2) (). Since most of the γ-secretase components contain several transmembrane domains, their presence in CSF was not assessed until recently. PS1 is a transmembrane aspartyl protease and the catalytic subunit of γ-secretase, and it is known to undergo endoproteolytic cleavage as part of its maturation, generating N- and C-terminal fragments (NTF and CTF) (56), with six- and three-transmembrane domains, respectively (57). APH1 also displays seven-transmembrane domains and PEN2 two transmembrane domains; only nicastrin contains a single transmembrane domain [for a review, see Ref. (58)]. Previously, the presence of soluble CTF–PS1 was reported in the media from cultured neurons (59). Recently, we demonstrated the presence of 100–150-kDa heteromeric complexes in CSF, composed of NTF and CTF PS1 [(); see also Figure 1B]. The presence of the NTF and 20-kDa CTF fragments was only clearly detectable in post-mortem CSF, where artifacts are likely to appear. APH1 and PEN2, but not nicastrin, co-exist within these CSF–PS1 complexes. We were unable to detect γ-secretase activity in human CSF, and presumed that CSF–PS1 complexes may result from non-specific aggregation of these transmembrane proteins with large numbers of hydrophobic regions. PS1 aggregates have previously been described as temperature-sensitive (60); similarly, CSF–PS1 complexes are only detectable when denaturation before electrophoresis is conducted at 50°C (15 min). Thus, analysis performed with samples denatured at 98°C can underestimate and fail to detect PS1 complexes. Ultracentrifugation in sucrose density gradients confirmed the existence of stable complexes of 100–150-kDa, but also showed that large complexes, which sediment in regions closer to 200 and 250 kDa, are unstable during electrophoresis under denaturing conditions. Interestingly, when we assessed whether CSF–PS1 levels are altered in AD, ventricular post-mortem samples (disease at term) display higher levels of PS1 than those present in non-demented control cases, particularly the stable complexes resolved by sucrose density gradients. Lumbar CSF samples from probable AD cases (early stages of the disease) display only significant differences in the proportion of the PS1 stable complex, but not in total levels (). The amount of PS1 stable complexes correlates with Aβ42. Our results suggest that the early and more significant phenomenon is the change in the dynamics of the assembly of PS1 complexes. The change in the proportion of stable complexes appears as a better marker for discriminating pathological samples than the estimation of total PS1 protein levels. Further characterization of CSF–PS1 complexes has yet to be conducted in order to define the appropriate methodological approach for evaluating their feasibility as a potential new AD biomarker, as well evaluation of its diagnostic performance in comparison with existing biomarkers such as Aβ.
Conclusion
Because CSF is in direct contact with the extracellular space of the central nervous system, biochemical changes in the brain could potentially be reflected in CSF. It is expected that potential AD biomarkers involved in AD pathogenesis will mirror AD progression. However, to date, no single biomarker has reached expectations. Several models of CSF secretion have been proposed (61–63), but the relationship with protein content and cellular origin of CSF protein composition remains unclear. Moreover, increasing evidence indicates the occurrence of soluble full-length membrane proteins in CSF. The mechanisms by which these membrane-bound proteins reached the CSF are unknown. Active secretion is unlikely, and it is still unclear if passive release from brain cells or neuronal death may be major contributing factors, as recently observed for BACE1 (). Most of these forms could display self-association properties based on hydrophobic and/or ionic interactions, resulting in the formation of complexes. Indeed, proteins like presenilins, with large numbers of hydrophobic regions, may be highly unstable in CSF, and spontaneously form complexes. The occurrence of different types of protein complexes in CSF, forming heterogeneous components, should be considered to accurately determine their levels. In this sense, the presence in CSF of soluble oligomers, normally associated with protein-misfolding diseases, has been suggested for multiple sclerosis patients (64).
Our understanding of the potential roles for APP, BACE1, ADAM proteins, PS1, and other related proteins in CSF is lacking, but of interest in order to design adequate quantification strategies to assess their real potential as biomarkers for AD. Ultimately, it is anticipated that a combination of CSF biomarkers might serve for early diagnosis, but also for assessing disease progression and especially the efficiency of secretase inhibitors during the course of clinical trials. In this review, we presented evidence that most of the proteins related with APP processing are measurable in CSF. More investigation should focus on the possibility of monitoring soluble forms of APP and secretase components, and to evaluate the progress and feasibility of developing molecular tools for these potential new CSF biomarkers for AD.
Statements
Acknowledgments
This study was funded in part by the EU BIOMARKAPD-Joint Programming on Neurodegenerative Diseases (JPND) project. This project is supported through the Instituto de Salud Carlos III (ISCIII; grants PI11/03026 to JS-V), cofinanced by the Fondo Europeo de Desarrollo Regional (FEDER), and under the aegis of JPND, and through CIBERNED, ISC-III.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BlennowKDuboisBFaganAMLewczukPde LeonMJHampelH. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement (2015) 11:58–69.10.1016/j.jalz.2014.02.004
2
BlennowKHampelHWeinerMZetterbergH. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6:131–44.10.1038/nrneurol.2010.4
3
RosenCHanssonOBlennowKZetterbergH. Fluid biomarkers in Alzheimer’s disease – current concepts. Mol Neurodegener (2013) 8:20.10.1186/1750-1326-8-20
4
HardyJSelkoeDJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science (2002) 297:353–6.10.1126/science.1072994
5
SteinerHFluhrerRHaassC. Intramembrane proteolysis by gamma-secretase. J Biol Chem (2008) 283:29627–31.10.1074/jbc.R800010200
6
ThinakaranGKooEH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem (2008) 283:29615–9.10.1074/jbc.R800019200
7
PorteliusEPriceEBrinkmalmGStitelerMOlssonMPerssonRet alA novel pathway for amyloid precursor protein processing. Neurobiol Aging (2011) 32:1090–8.10.1016/j.neurobiolaging.2009.06.002
8
JackCRJrKnopmanDSJagustWJShawLMAisenPSWeinerMWet alHypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol (2010) 9:119–28.10.1016/S1474-4422(09)70299-6
9
WolfeMS. γ-Secretase as a target for Alzheimer’s disease. Adv Pharmacol (2012) 64:127–53.10.1016/B978-0-12-394816-8.00004-0
10
YanRVassarR. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol (2014) 13:319–29.10.1016/S1474-4422(13)70276-X
11
PalmertMRPodlisnyMBWitkerDSOltersdorfTYounkinLHSelkoeDJet alThe beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci U S A (1989) 86:6338–42.10.1073/pnas.86.16.6338
12
GhisoJTagliaviniFTimmersWFFrangioneB. Alzheimer’s disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization. Biochem Biophys Res Commun (1989) 163:430–7.10.1016/0006-291X(89)92154-2
13
PerneczkyRAlexopoulosPKurzA. Soluble amyloid precursor proteins and secretases as Alzheimer’s disease biomarkers. Trends Mol Med (2014) 20:8–15.10.1016/j.molmed.2013.10.001
14
EfthimiopoulosSVassilacopoulouDRipellinoJATezapsidisNRobakisNK. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc Natl Acad Sci U S A (1996) 93:8046–50.10.1073/pnas.93.15.8046
15
TezapsidisNLiHCRipellinoJAEfthimiopoulosSVassilacopoulouDSambamurtiKet alRelease of nontransmembrane full-length Alzheimer’s amyloid precursor protein from the lumenar surface of chromaffin granule membranes. Biochemistry (1998) 37:1274–82.10.1021/bi9714159
16
Cuchillo-IbañezILopez-FontIBoix-AmorósABrinkmalmGBlennowKMolinuevoJLet alHeteromers of amyloid precursor protein in cerebrospinal fluid. Mol Neurodegener (2015) 10:2.10.1186/1750-1326-10-2
17
LewczukPKamrowski-KruckHPetersOHeuserIJessenFPoppJet alSoluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatry (2010) 15:138–45.10.1038/mp.2008.84
18
GabelleARocheSGényCBennysKLabaugePTholanceYet alCorrelations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Res (2010) 21:175–83.10.1016/j.brainres.2010.08.022
19
MulugetaELondosEHanssonOBallardCSkogsethRMinthonLet alCerebrospinal fluid levels of sAPPα and sAPPβ in Lewy body and Alzheimer’s disease: clinical and neurochemical correlates. Int J Alzheimers Dis (2011) 2011:495025.10.4061/2011/495025
20
AlexopoulosPTsolakidouARoselliFArnoldAGrimmerTWesterteicherCet alClinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement (2012) 8:304–11.10.1016/j.jalz.2011.04.009
21
SennvikKFastbomJBlombergMWahlundLOWinbladBBenedikzE. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett (2000) 278:169–72.10.1016/S0304-3940(99)00929-5
22
BlennowK. Biomarkers in Alzheimer’s disease drug development. Nat Med (2010) 16:1218–22.10.1038/nm.2221
23
KarranEHardyJ. Antiamyloid therapy for Alzheimer’s disease – are we on the right road?N Engl J Med (2014) 370:377–8.10.1056/NEJMe1313943
24
MayPCDeanRALoweSLMartenyiFSheehanSMBoggsLNet alRobust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci (2011) 31:16507–16.10.1523/JNEUROSCI.3647-11.2011
25
García-AyllónMSCampanariMLBrinkmalmGRábanoAAlomJSauraCAet alCSF presenilin-1 complexes are increased in Alzheimer’s disease. Acta Neuropathol Commun (2013) 1:46.10.1186/2051-5960-1-46
26
TanakaSNakamuraSUedaKKameyamaMShiojiriSTakahashiYet alThree types of amyloid protein precursor mRNA in human brain: their differential expression in Alzheimer’s disease. Biochem Biophys Res Commun (1988) 157:472–9.10.1016/S0006-291X(88)80273-0
27
DobrowolskaJAMichenerMSWuGPattersonBWChottROvodVet alCNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition. J Neurosci (2014) 34:8336–46.10.1523/JNEUROSCI.0540-14.2014
28
VassarRKovacsDMYanRWongPC. The beta-secretase enzyme BACE in health and Alzheimer’s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci (2009) 29:12787–94.10.1523/JNEUROSCI.3657-09.2009
29
DominguezDTournoyJHartmannDHuthTCrynsKDeforceSet alPhenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem (2005) 280:30797–806.10.1074/jbc.M505249200
30
HaqueABanikNLRaySK. New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer’s disease: cathepsin inhibitors as potential therapeutics. CNS Neurol Disord Drug Targets (2008) 7:270–7.10.2174/187152708784936653
31
HolsingerRMMcLeanCACollinsSJMastersCLEvinG. Increased beta-secretase activity in cerebrospinal fluid of Alzheimer’s disease subjects. Ann Neurol (2004) 55:898–9.10.1002/ana.20144
32
DecourtBSabbaghMN. BACE1 as a potential biomarker for Alzheimer’s disease. J Alzheimers Dis (2011) 24(Suppl 2):53–9.10.3233/JAD-2011-110017
33
ZhongZEwersMTeipelSBürgerKWallinABlennowKet alLevels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 64:718–26.10.1001/archpsyc.64.6.718
34
ZetterbergHAndreassonUHanssonOWuGSankaranarayananSAnderssonMEet alElevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 65:1102–7.10.1001/archneur.65.8.1102
35
BenjannetSElagozAWickhamLMamarbachiMMunzerJSBasakAet alPost-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem (2001) 276:10879–87.10.1074/jbc.M009899200
36
HussainIHawkinsJShikotraARiddellDRFallerADingwallC. Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). J Biol Chem (2003) 278:36264–8.10.1074/jbc.M304186200
37
VerheijenJHHuismanLGNeumannUPaganettiPHackCEBouwmanF. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem (2006) 52:1168–74.10.1373/clinchem.2006.066720
38
WuGSankaranarayananSTugushevaKKahanaJSeabrookGShiXPet alDecrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer’s subjects. Clin Biochem (2008) 41:986–96.10.1016/j.clinbiochem.2008.04.022
39
WuGSankaranarayananSWongJTugushevaKMichenerMSShiXet alCharacterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer’s disease. J Neurosci Res (2012) 90:2247–58.10.1002/jnr.23122
40
MurayamaKSKametaniFArakiW. Extracellular release of BACE1 holoproteins from human neuronal cells. Biochem Biophys Res Commun (2005) 338:800–7.10.1016/j.bbrc.2005.10.015
41
SchmechelAStraussMSchlicksuppAPipkornRHaassCBayerTAet alHuman BACE forms dimers and colocalizes with APP. J Biol Chem (2004) 279:39710–7.10.1074/jbc.M402785200
42
WestmeyerGGWillemMLichtenthalerSFLurmanGMulthaupGAssfalg-MachleidtIet alDimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. J Biol Chem (2004) 279:53205–12.10.1074/jbc.M410378200
43
BarãoSZhouLAdamczukKVanhoutvinTvan LeuvenFDemedtsDet alBACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr Alzheimer Res (2013) 10:671–8.10.2174/15672050113109990138
44
VingtdeuxVMarambaudP. Identification and biology of α-secretase. J Neurochem (2012) 120:34–45.10.1111/j.1471-4159.2011.07477.x
45
NausSReipschlägerSWildeboerDLichtenthalerSFMitterreiterSGuanZet alIdentification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem (2006) 387:337–46.10.1515/BC.2006.045
46
JorissenEProxJBernreutherCWeberSSchwanbeckRSerneelsLet alThe disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci (2010) 30:4833–44.10.1523/JNEUROSCI.5221-09.2010
47
KuhnPHWangHDislichBColomboAZeitschelUEllwartJWet alADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J (2010) 29:3020–32.10.1038/emboj.2010.167
48
ColciaghiFBorroniBPastorinoLMarcelloEZimmermannMCattabeniFet alα-Secretase ADAM10 as well as αAPPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med (2002) 8:67–74.
49
EdwardsDRHandsleyMMPenningtonCJ. The ADAM metalloproteinases. Mol Aspects Med (2008) 29:258–89.10.1016/j.mam.2008.08.001
50
JiangHHampelHPrvulovicDWallinABlennowKLiRet alElevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Mol Neurodegener (2011) 6:69.10.1186/1750-1326-6-69
51
BaiLSongNYuJTanLShenYXieJet alElevated plasma levels of soluble TNFRs and TACE activity in Alzheimer’s disease patients of Northern Han Chinese descent. Curr Alzheimer Res (2013) 10:57–62.10.2174/1567205011310010008
52
SunQHampelHBlennowKListaSLeveyATangBet alIncreased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer’s disease. J Alzheimers Dis (2014) 41:877–86.10.3233/JAD-140177
53
PeschonJJSlackJLReddyPStockingKLSunnarborgSWLeeDCet alAn essential role for ectodomain shedding in mammalian development. Science (1998) 282:1281–4.10.1126/science.282.5392.1281
54
StoeckAKellerSRiedleSSandersonMPRunzSLe NaourFet alA role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J (2006) 393:609–18.10.1042/BJ20051013
55
KaetherCHaassCSteinerH. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis (2006) 3:275–83.10.1159/000095267
56
ThinakaranGBorcheltDRLeeMKSluntHHSpitzerLKimGet alEndoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 17:181–90.10.1016/S0896-6273(00)80291-3
57
LaudonHHanssonEMMelénKBergmanAFarmeryMRWinbladBet alA nine-transmembrane domain topology for presenilin 1. J Biol Chem (2005) 280:35352–60.10.1074/jbc.M507217200
58
WakabayashiTDe StrooperB. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) (2008) 23:194–204.10.1152/physiol.00009.2008
59
BenussiLAlbericiAMayhausMLangerUGhidoniRMazzoliFet alDetection of the presenilin 1 COOH-terminal fragment in the extracellular compartment: a release enhanced by apoptosis. Exp Cell Res (2001) 269:256–65.10.1006/excr.2001.5329
60
De StrooperBBeullensMContrerasBLevesqueLCraessaertsKCordellBet alPhosphorylation, subcellular localization, and membrane orientation of the Alzheimer’s disease-associated presenilins. J Biol Chem (1997) 272:3590–8.10.1074/jbc.272.6.3590
61
OreskovićDKlaricaM. The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res Rev (2010) 64:241–62.10.1016/j.brainresrev.2010.04.006
62
DamkierHHBrownPDPraetoriusJ. Cerebrospinal fluid secretion by the choroid plexus. Physiol Rev (2013) 93:1847–92.10.1152/physrev.00004.2013
63
LehtinenMKBjornssonCSDymeckiSMGilbertsonRJHoltzmanDMMonukiES. The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. J Neurosci (2013) 33:17553–9.10.1523/JNEUROSCI.3258-13.2013
64
DavidMATayebiM. Detection of protein aggregates in brain and cerebrospinal fluid derived from multiple sclerosis patients. Front Neurol (2014) 5:251.10.3389/fneur.2014.00251
Summary
Keywords
Alzheimer’s disease, cerebrospinal fluid, BACE1, soluble amyloid precursor protein, presenilin-1, TACE
Citation
Lopez-Font I, Cuchillo-Ibañez I, Sogorb-Esteve A, García-Ayllón M-S and Sáez-Valero J (2015) Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer’s Disease. Front. Neurol. 6:125. doi: 10.3389/fneur.2015.00125
Received
24 March 2015
Accepted
17 May 2015
Published
02 June 2015
Volume
6 - 2015
Edited by
Charlotte Elisabeth Teunissen, VU University Medical Center Amsterdam, Netherlands
Reviewed by
Scott Ayton, Florey Neuroscience Institute, Australia; Henrik Zetterberg, The Sahlgrenska Academy at the University of Gothenburg, Sweden
Copyright
© 2015 Lopez-Font, Cuchillo-Ibañez, Sogorb-Esteve, García-Ayllón and Sáez-Valero.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Javier Sáez-Valero, Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, Av. Ramón y Cajal s/n, Sant Joan d’Alacant E-03550, Spain, j.saez@umh.es
Specialty section: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.